FY26 ffrdc leases
Ended Awarded Last action
- Contract number
- 75N91025F00005
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $28,530,382
Award facts
- Opportunity
-
- NCINCIFOSO250099 Solicitation number
- Contract value 100% obligated
- $28,530,382.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $89,208 | |
| Funding Only Action | $647,872 | |
| Original award | $27,793,302 |
About this award
The National Cancer Institute issued a delivery order to Leidos Biomedical Research Inc. on August 31, 2025, with a ceiling value of $28.53 million under a Federally Funded Research and Development Center (FFRDC) lease arrangement, completion August 30, 2026.
Place of performance is Frederick, MD. The order is priced on a cost-plus-fixed-fee basis with no set-aside. Leidos Biomedical Research operates the Frederick National Laboratory for Cancer Research on behalf of NCI and delivers biomedical research execution, facilities infrastructure management, clinical trial support, and specialized manufacturing across the Frederick campus and subordinate NIH collaborative sites.
Service Contract Inventory reporting for this order shows $1.8 million invoiced in FY2025 with zero reported FTEs, indicating the invoiced activity reflects non-labor or administrative cost flow in the initial reporting period. No subcontractors were reported for SCI purposes; Leidos self-performed all activity captured in that fiscal year.
Quick answers
Who was awarded contract 75N91025F00005?
75N91025F00005 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on August 31, 2025.
How much is contract 75N91025F00005 worth?
The government has obligated $28,530,382 on 75N91025F00005.
Is contract 75N91025F00005 an order under another contract?
Yes. 75N91025F00005 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91025F00005 competed?
The extent of competition for 75N91025F00005 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award